BACKGROUND: Tuberculosis (TB) and HIV rates continue to escalate in Russia, but true rates for drug resistance, especially multidrug resistant tuberculosis (MDR TB), are unknown. A study was conducted with the aims of identifying first line drug resistance, both in the civilian and prison sectors, for new and previously treated cases; and risk factors for the development of drug resistance. METHODS: A cross sectional survey was undertaken of 600 patients (309 civilians, 291 prisoners) with bacteriologically confirmed pulmonary TB over a 1 year period during 2001-2 in Samara Oblast, Russia. RESULTS: The prevalence of isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide resistance in new TB cases (civilian and prison patients) was 38.0%, 25.2%, 34.6%, 14.7%, and 7.2%, respectively. The prevalence of MDR TB was 22.7%, 19.8%, and 37.3% in all new cases, new civilian cases, and new prison cases, respectively, with an overall prevalence of 45.5% and 55.3% in previously treated cases. Factors associated with resistance included previous TB treatment for more than 4 weeks, smoking (for isoniazid resistance), the presence of cavitations on the chest radiograph, and imprisonment. HIV was not associated with resistance in all patients. The rates of resistance were significantly higher in prisoners, with rate ratios (RR) of 1.9 (95% CI 1.1 to 3.2) for MDR TB, 1.9 (95% CI 1.1 to 3.2) for rifampicin, and 1.6 (95% CI 1.0 to 2.6) for isoniazid. CONCLUSIONS: Rates of first line drug resistance are high, particularly in prisoners and previously treated cases. TB control programmes should initially focus on standardised treatment to maximise cure, combined with measures to reduce institutional TB spread (particularly in prisons) coupled with early diagnosis of MDR TB to reduce the spread and development of resistance.
BACKGROUND:Tuberculosis (TB) and HIV rates continue to escalate in Russia, but true rates for drug resistance, especially multidrug resistant tuberculosis (MDR TB), are unknown. A study was conducted with the aims of identifying first line drug resistance, both in the civilian and prison sectors, for new and previously treated cases; and risk factors for the development of drug resistance. METHODS: A cross sectional survey was undertaken of 600 patients (309 civilians, 291 prisoners) with bacteriologically confirmed pulmonary TB over a 1 year period during 2001-2 in Samara Oblast, Russia. RESULTS: The prevalence of isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide resistance in new TB cases (civilian and prison patients) was 38.0%, 25.2%, 34.6%, 14.7%, and 7.2%, respectively. The prevalence of MDR TB was 22.7%, 19.8%, and 37.3% in all new cases, new civilian cases, and new prison cases, respectively, with an overall prevalence of 45.5% and 55.3% in previously treated cases. Factors associated with resistance included previous TB treatment for more than 4 weeks, smoking (for isoniazid resistance), the presence of cavitations on the chest radiograph, and imprisonment. HIV was not associated with resistance in all patients. The rates of resistance were significantly higher in prisoners, with rate ratios (RR) of 1.9 (95% CI 1.1 to 3.2) for MDR TB, 1.9 (95% CI 1.1 to 3.2) for rifampicin, and 1.6 (95% CI 1.0 to 2.6) for isoniazid. CONCLUSIONS: Rates of first line drug resistance are high, particularly in prisoners and previously treated cases. TB control programmes should initially focus on standardised treatment to maximise cure, combined with measures to reduce institutional TB spread (particularly in prisons) coupled with early diagnosis of MDR TB to reduce the spread and development of resistance.
Authors: Christopher Dye; Marcos A Espinal; Catherine J Watt; Cyrille Mbiaga; Brian G Williams Journal: J Infect Dis Date: 2002-04-01 Impact factor: 5.226
Authors: A M Johnson; C H Mercer; B Erens; A J Copas; S McManus; K Wellings; K A Fenton; C Korovessis; W Macdowall; K Nanchahal; S Purdon; J Field Journal: Lancet Date: 2001-12-01 Impact factor: 79.321
Authors: P Spradling; D Drociuk; S McLaughlin; L M Lee; C A Peloquin; K Gallicano; C Pozsik; I Onorato; K G Castro; R Ridzon Journal: Clin Infect Dis Date: 2002-10-10 Impact factor: 9.079
Authors: T Djuretic; J Herbert; F Drobniewski; M Yates; E G Smith; J G Magee; R Williams; P Flanagan; B Watt; A Rayner; M Crowe; M V Chadwick; A M Middleton; J M Watson Journal: Thorax Date: 2002-06 Impact factor: 9.139
Authors: Y Lin; L-X Wang; L-X Qiu; Q Huang; Q Shu; H-X Lin; X Meng; X-L Zeng; L-X Xiao; T S Bam; C-Y Chiang Journal: Public Health Action Date: 2015-09-21
Authors: Y Balabanova; M Ruddy; J Hubb; M Yates; N Malomanova; I Fedorin; F Drobniewski Journal: Eur J Clin Microbiol Infect Dis Date: 2005-02 Impact factor: 3.267
Authors: Desiree T B D'souza; Nerges F Mistry; Tina S Vira; Yatin Dholakia; Sven Hoffner; Geoffrey Pasvol; Mark Nicol; Robert J Wilkinson Journal: BMC Public Health Date: 2009-06-29 Impact factor: 3.295
Authors: Jae Chol Choi; Song Yong Lim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Nam Yong Lee; Young Kil Park; Gil Han Bai; Won Jung Koh Journal: J Korean Med Sci Date: 2007-08 Impact factor: 2.153